Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis  by Price, Ric N et al.
982 www.thelancet.com/infection   Vol 14   October 2014
Articles
Global extent of chloroquine-resistant Plasmodium vivax: 
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Ric N Price, Lorenz von Seidlein, Neena Valecha, Francois Nosten, J Kevin Baird, Nicholas J White
Summary
Background Chloroquine is the ﬁ rst-line treatment for Plasmodium vivax malaria in most endemic countries, but 
resistance is increasing. Monitoring of antimalarial eﬃ  cacy is essential, but in P vivax infections the assessment of 
treatment eﬃ  cacy is confounded by relapse from the dormant liver stages. We systematically reviewed P vivax malaria 
treatment eﬃ  cacy studies to establish the global extent of chloroquine resistance.
Methods We searched Medline, Web of Science, Embase, and the Cochrane Database of Systematic Reviews to 
identify studies published in English between Jan 1, 1960, and April 30, 2014, which investigated antimalarial 
treatment eﬃ  cacy in P vivax malaria. We excluded studies that did not include supervised schizonticidal treatment 
without primaquine. We determined rates of chloroquine resistance according to P vivax malaria recurrence rates 
by day 28 whole-blood chloroquine concentrations at the time of recurrence and study enrolment criteria.
Findings We identiﬁ ed 129 eligible clinical trials involving 21 694 patients at 179 study sites and 26 case reports 
describing 54 patients. Chloroquine resistance was present in 58 (53%) of 113 assessable study sites, spread across 
most countries that are endemic for P vivax. Clearance of parasitaemia assessed by microscopy in 95% of patients by 
day 2, or all patients by day 3, was 100% predictive of chloroquine sensitivity. 
Interpretation Heterogeneity of study design and analysis has confounded global surveillance of chloroquine-resistant 
P vivax, which is now present across most countries endemic for P vivax. Improved methods for monitoring of drug 
resistance are needed to inform antimalarial policy in these regions.
Funding Wellcome Trust (UK).
Copyright © Price et al. Open Access article distributed under the terms of CC BY
Introduction
Plasmodium vivax is a major cause of morbidity, causing 
72–390 million clinical cases of malaria worldwide each 
year.1,2 Vivax malaria is an important cause of morbidity, 
especially in young children, with adverse consequences 
for education, development, and wellbeing. Unlike 
Plasmodium falciparum malaria, P vivax forms dormant 
liver stages (hypnozoites), which cause relapses of 
infection weeks to months after the initial attack. In 
some areas, recurrent infections can occur as often as 
every 3 weeks, with relapses the main cause of vivax 
illness. Acute febrile episodes are associated with 
anaemia, intrauterine growth retardation,3 miscarriage, 
and severe and fatal disease.4–7
Policy makers and malaria researchers have generally 
focused on P falciparum, which is the main cause of 
malaria mortality. Substantial progress has been made in 
reduction of the global burden of malaria, much of which 
has been attributed to increases in access to health-care 
services, early diagnosis, treatment with highly eﬀ ective 
antimalarial drug regimens, and deployment of 
insecticide-treated bednets. One of the greatest threats to 
control and elimination eﬀ orts is the emergence and 
spread of antimalarial drug resistance. This recurring 
problem has plagued malaria therapeutics for more than 
60 years. In the early 1950s, chloroquine became 
established as the best antimalarial drug for all human 
malarias, but within a decade resistance had emerged. 
Chloroquine-resistant P falciparum spread throughout 
malaria-endemic countries killing millions of people. 
Antimalarial drug resistance is measured by the pre-
valence and severity of treatment failure. In P falciparum 
malaria recrudescent infection is deﬁ ned as the re-
emergence of a genetically identical parasite in the 
peripheral blood after its initial treatment with a usually 
curative drug regimen (thereby distinguishing it from a 
newly acquired infection). P vivax clinical eﬃ  cacy studies 
are more diﬃ  cult to interpret, because recurrent 
infections can arise from recrudescence, reinfection, or 
relapses (arising from the dormant liver stages).8 
Relapses can be prevented only by 8-aminoquinolines 
such as primaquine.
Chloroquine is the ﬁ rst-line treatment for P vivax 
malaria in most endemic countries. When given with 
primaquine (radical cure), the combination is highly 
eﬀ ective against both the acute illness and in prevention 
of relapses from hypnozoites. Chloroquine-resistant 
P vivax was ﬁ rst reported in 1989, almost 30 years after 
chloroquine-resistant P falciparum was ﬁ rst noted.9,10 The 
absence of reliable, robust, sensitive methods for 
detection, mapping, and monitoring of antimalarial drug 
eﬃ  cacy in P vivax has almost certainly contributed to the 
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delayed recognition of this emerging problem.11 This 
delay has had important public health implications. In 
areas where high-grade chloroquine-resistant P vivax is 
prevalent (such as Indonesia and Oceania), partly 
eﬀ ective drug treatments and consequent recurrent 
infections are an important contributing factor to severe 
anaemia from P vivax malaria.12 Recognition and 
deﬁ nition of the scale of the problem is key for treatment 
guidelines to be revised and appropriate control and 
elimination strategies to be devised and implemented. In 
this Article, we present a systematic review and meta-
analysis of P vivax drug trials that summarises the 
geographical extent and level of evidence for reduced 
P vivax susceptibility to chloroquine and estimate risk of 
recurrence by day 28.
Methods
Study design
Our analysis adhered to the recommendations of the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines.13 We systematically 
searched Medline, Web of Science, Embase, and the 
Cochrane Database of Systematic Reviews to identify 
studies of chloroquine treatment of vivax malaria 
published in English between Jan 1, 1960, and April 30, 
2014. A complete list of the search terms and the 
antimalarial clinical trials identiﬁ ed is presented online 
by the WorldWide Antimalarial Resistance Network 
(WWARN).14 We ﬁ ltered this database for clinical studies 
containing “vivax” in the title or abstract. Reference lists 
of previously published reviews and papers on 
chloroquine-resistant P vivax were also screened for 
relevant studies in English.
We systematically extracted data on study charac-
teristics, recurrence, and side-eﬀ ects from the articles 
and entered into an EpiInfo database (version 3.5.1). We 
extracted the study method, including location of study 
site, inclusion and exclusion criteria, clinical setting, 
randomisation and masking, and the chloroquine dose 
regimen (dose, frequency, duration, and supervision of 
treatment), and the co-administration of primaquine; 
these data are available online.15 We identiﬁ ed study sites 
with Google Earth. We excluded antirelapse studies that 
did not include a treatment group without primaquine, 
and studies in which treatment was not supervised. 
We extracted estimates of chloroquine eﬃ  cacy and 
present them separately for each treatment group at each 
study location (termed site estimates). The primary 
outcome measure was the risk of recurrent P vivax 
parasitaemia at day 28. Results of previous studies have 
shown that the prolonged elimination of chloroquine 
provides blood concentrations that prevent recurrence of 
chloroquine-sensitive P vivax for about 35 days. Hence, 
no recurrent parasitaemia should be noted within 28 days 
of treatment in patients taking a complete treatment 
course with adequate absorption.16 The proportion of 
patients with recurrent P vivax parasitaemia by day 28 is 
therefore a useful measure of chloroquine resistance, 
whether recurrence is caused by recrudescence, relapse, 
or a new infection. Secondary outcome measures 
included the proportion of patients with parasitaemia on 
days 1, 2, and 3; the day of the ﬁ rst recurrence; and the 
proportion of patients with early treatment failure, 
deﬁ ned according to WHO criteria for P falciparum.8,17
We separated chloroquine resistance a priori into four 
categories according to the primary outcome. Category 1 
resistance constituted greater than 10% recurrences by 
day 28 (with a lower 95% CI of >5%), irrespective of 
conﬁ rmation of adequate blood chloroquine con cen-
tration; occasional breakthrough recurrences do occur 
within 28 days of chloroquine treatment, but a risk 
greater than 10% in a large enough sample is very 
suggestive of resistance. Category 2 resistance included 
conﬁ rmation of recurrences within 28 days, in the 
presence of whole-blood chloroquine concentrations 
greater than 100 nm;16 parasite growth in the presence of 
high blood concentrations of the drug conﬁ rms 
resistance. Category 3 resistance included at least 5% 
recurrences by day 28 (lower 95% CI of <5%), irrespective 
of conﬁ rmation of adequate blood chloroquine 
Figure 1: Study selection
15 522 studies identiﬁed after search of Medline, Web
of Science, Embase, and the Cochrane Database 
of Systematic Reviews for “antimalarials”
  1172 antimalarial clinical eﬃcacy studies identiﬁed
197 studies enrolled patients with Plasmodium vivax
129 studies
114 schizonticidal eﬃcacy trials
9 antirelapse eﬃcacy with control group
6 schizonticidal and antirelapse eﬃcacy
230 treatment groups
12 schizonticidal studies excluded
11 full text articles not available
1 eﬀectiveness study
56 antirelapse studies excluded
7 full text not available
1 presumptive diagnosis
1 postexposure study
2 passive follow-up
5 volunteer study
8 no sampling in ﬁrst 28 days
32 no control group (schizonticidal  only)
194 non-artemisinin regimens
144 chloroquine
6 meﬂoquine
6 halofantrine
9 sulfadoxine with pyrimethamine
2 amodiaquine
3 atovaquone with proguanil
24 other
36 artemisinin regimens
9 dihydroatemisinin with piperaquine
7 artemether with lumefantrine
3 artesunate plus sulfadoxine
1 amodiaquine with artesunate
1 pyronandine with artesunate
1 artemisinin naphthoquine
14 artemisinin monotherapy
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concentration; this category suggests potential evidence 
of chloroquine resistance, but might result from other 
factors such as poor drug absorption or drug quality. In 
category 4, chloroquine sensitivity was conﬁ rmed if 
patients had enrolled after a symptomatic clinical illness, 
fewer than 5% recurrences had occurred by day 28, no 
primaquine was given before day 28, and studies had a 
sample size of at least ten patients.
Statistical analysis
We restricted analysis of drug eﬃ  cacy to patients treated 
with a chloroquine regimen. We calculated the risk of 
recurrence per protocol with the number of patients with 
recurrent P vivax during 28 days of follow-up, with the 
denominator being the number of patients followed until 
the study endpoint. We estimated the risk of recurrence 
for each chloroquine group, stratiﬁ ed by study location. 
We estimated the eﬀ ect of primaquine by comparing 
recurrence rates in randomised studies in which patients 
were treated with and without concomitant primaquine. 
We estimated the comparative risk of recurrence by 
day 28 as Mantel-Haenszel odds ratios with Review 
Manager version 5.2. We analysed all data with SPSS v19.0 
for Windows.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
RNP had full access to all the data in the study, and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
We identiﬁ ed 198 clinical trials enrolling patients with 
P vivax, of which we excluded 68 (ﬁ gure 1). Of the 
129 clinical trials included, 115 were designed primarily 
to establish eﬃ  cacy against P vivax blood stages 
(schizonticidal activity). 14 studies were designed as 
antirelapse studies to assess the radical curative eﬃ  cacy 
of primaquine or tafenoquine, but also enrolled a 
chloroquine-only comparative treatment group (nine 
studies) or were designed to estimate both schizonticidal 
and antirelapse eﬃ  cacy (six studies). In 89 (69%) of 
129 studies, patients were recruited from outpatient 
clinics; however, in 19 (15%) studies, patients were 
enrolled from hospitals, and in 21 (16%) studies, patients 
were recruited from cross-sectional surveys. Patients 
recruited from surveys had lower baseline parasitaemia 
(median 799 per μL, IQR 367–1043) than did those 
recruited from hospital (9830 per μL, IQR 5634–13 830; 
p=0∙002), or outpatient clinics (4057 per μL, IQR 
2800–5514; p=0∙002). We assessed 230 treatment groups 
at 179 study sites, enrolling 21 694 patients. Chloroquine 
was included in 144 treatment groups (63%; 
15 455 patients), sulfadoxine with pyrimethamine in nine 
treatment groups (3·9%; 486 patients), dihydro-
artemisinin with piperaquine in nine treatment groups 
(3·9%; 1132 patients), artemether with lumefantrine in 
seven treatment groups (3·0%; 1092 patients), 
meﬂ oquine in six treatment groups (2·6%; 377 patients), 
and halofantrine in six treatment groups (2·6%; 
222 patients).
We noted heterogeneity in the design of the clinical 
studies (table 1). 55 publications reported comparative 
drug trials, of which 45 (82%) were randomised. The 
median number of comparative treatment groups was 
two (range 2–10). Age-related inclusion criteria were 
recorded for 87 (67%) studies; children younger than 
5 years were excluded from 48 (37%) studies. Parasite 
density was an enrolment criterion in 52 (40%) studies, 
the inclusion threshold varying from at least 40 asexual 
parasites per μL to at least 5000 per μL. Patients with 
recent treatment were excluded from 52 (40%) studies. 
The median duration of follow-up was 28 days (range 
14–365). Venous drug concentrations were measured in 
39 (30%) studies, and genotyping was applied to the 
analysis of ten (8%) studies.
The standard dose was a 3 day regimen of chloroquine 
(total dose 25 mg base/kg), although in eight treatment 
groups (583 patients) the same total dose was spread over 
four doses, and in ﬁ ve treatment groups (1595 patients) 
only a single dose of 7∙5–10 mg/kg of chloroquine was 
given. In four treatment groups, chloroquine was given 
with sulfadoxine and pyrimethamine, and in one group 
given with a 7 day course of doxycycline. Primaquine was 
given in 73 (51%) chloroquine treatment groups: a very 
Clinical 
studies
Treatment 
groups
Site estimates of 
chloroquine eﬃ  cacy
Location
Asia 104 195 134
Africa 10 13 13
South America 14 16 22
Multicentre 1 6 8
Overall 129 230 177
Year of publication
1981–90 6 19 8
1991–00 34 68 41
2001–10 65 105 80
2011–14 24 38 48
Origin of patients enrolled
Community surveys 21 25 22
In hospital 19 46 21
Outpatient setting 89 159 134
Follow-up period*
<27 days 4 4 3
27–34 days 98 163 128
40–45 days 10 21 13
56–63 days 3 6 9
>80 days 12 34 23
*Maximum duration of follow-up not stated in two studies.
Table 1: Characteristics of selected studies
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high dose (13∙5 mg/kg total) in two groups, a high dose 
(6–7 mg/kg total dose) in eight groups, a low dose 
(2∙5–4 mg/kg total dose) in 49 groups, and a very low 
dose (1∙3 mg/kg total dose) in nine groups.14 The 
primaquine dose was not stated in ﬁ ve publications. The 
course of primaquine was started at the same time as 
chloroquine treatment in 21 groups, at the end of 
chloroquine treatment in 24 groups, and at the end of the 
study in 23 groups. In ﬁ ve groups primaquine was 
started during follow-up on day 7 (one group), day 14 
(three groups), and day 28 (one group).
14 studies included patients recruited into comparative 
studies of chloroquine monotherapy and chloroquine 
plus primaquine administered at the start of treatment. 
In three of these studies, two comparisons were made, 
and in two studies, four comparisons were made. In all 
but two of these studies patients receiving chloroquine 
plus primaquine had an equivalent or lower risk of 
P vivax recurrence by day 28 than did patients receiving 
chloroquine alone (ﬁ gure 2).
Estimates of chloroquine eﬃ  cacy could be derived for 
177 sites from 144 treatment groups. In 65 (37%) of these 
sites chloroquine resistance could not be categorised for 
the following reasons: early administration of primaquine 
(37 sites); no documentation of parasitological data at 
day 28 (15 sites); sample size of fewer than ten patients 
(four sites); good response documented in asymptomatic 
patients (four sites); and administration of only a single 
dose of chloroquine (ﬁ ve sites). Overall P vivax was 
deﬁ ned as chloroquine resistant for 57 (51%) of 112 site 
estimates, 35 (61%) of these sites fulﬁ lled the predeﬁ ned 
criteria for category 1 resistance, eight (14%) 
for category 2 resistance, and 14 (25%) for category 3 
resistance. The median risk of recurrence in these 
chloroquine-resistant sites was 16∙7% (IQR 9∙8–31∙4). 
The earliest treatment failure occurred at a median of 
14 days (range 3–28), and the interval was negatively 
correlated with both delayed parasite clearance (as 
deﬁ ned by the proportion of patients with peripheral 
parasitaemia at 48 h; rs=–0∙72, p=0∙002), and the risk of 
recurrent infections at day 28 (rs=–0∙58, p=0·005). These 
correlations remained signiﬁ cant after controlling for the 
place from which patients were recruited (hospital, 
outpatient, or survey).
Measures of early parasite clearance were documented 
in 99 (56%) of 177 site estimates, although the actual 
proportions of patients who had parasitaemia on days 1, 
2, and 3 could be deduced for only 60 (61%) of these site 
estimates. Sites where P vivax was categorised as being 
chloroquine-resistant (ﬁ gure 3) had a signiﬁ cantly higher 
proportion of patients with parasitaemia on day 2 
(median 25∙5%, range 6·0–73·0) compared with those 
categorised as chloroquine-sensitive (median 7∙0%, 
range 0–50·0; p=0∙006; ﬁ gure 4). The diﬀ erence was also 
evident at day 3 (3∙0%, 0∙9–29·0) for chloroquine-
resistant sites vs 0∙4%, 0–13∙7 for chloroquine-sensitive 
sites; p=0∙023). Clearance of parasitaemia (assessed by 
microscopy) in all patients by day 3, or in 95% of patients 
Figure 2: Forest plot of the risk of recurrence at day 28 in patients treated with chloroquine or chloroquine plus primaquine
High dose >6 mg/kg. Low dose 3–5 mg/kg. Very low dose <2 mg/kg. As part of a sensitivity analysis, studies in which no recurrences were recorded before day 28 were 
assigned a numerator of 1, the derived odds ratio was recalculated as 0·43 (95% CI 0·24–0·79; p=0·006). References for all studies are shown in the appendix.
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2·86 (0·12–70·36)
0·25 (0·03–2·27)
0·27 (0·11–0·70)
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by day 2, was 100% predictive of chloroquine sensitivity 
in the study population as deﬁ ned by day 28 recurrence. 
We identiﬁ ed 26 case reports of 54 patients with 
suspected chloroquine-resistant P vivax (appendix). In 
18 patients had breakthroughs during chloroquine 
prophylaxis were described (ﬁ ve in the presence of high 
blood chloroquine concentrations), twelve patients had 
reports of prolonged parasite clearance (eight in the 
Figure 3: Location of study sites with documented chloroquine-resistant (A) and chloroquine-sensitive Plasmodium vivax (B)
Thailand
Vietnam
South
Korea
Burma
(Myanmar)
Burma
(Myanmar)
Indonesia Papua New
Guinea
Turkey
India
Ethiopia
Madagascar
Colombia
Brazil 
Bolivia
Peru
Malaysia
Philippines
Japan
India
Ethiopia
Iran
Afghanistan
Pakistan
Colombia
Bolivia
Ecuador
Peru
A
B
Guyana
Thailand
Category 1
Category 2
Category 3
Case reports
Done before 2008
Done between 2008 and 2014
See Online for appendix
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presence of high blood chloroquine concentrations), and 
24 patients had recurrence of P vivax after treatment 
(seven with blood-chloroquine concentrations exceeding 
100 ng/mL at the time of recurrence). 20 cases had con-
ﬁ rmed parasite growth in blood chloroquine concentrations 
exceeding 100 ng/mL (ﬁ gure 3). Table 2 shows the 
publications referring to clinical trials and case reports 
with patients having early treatment failure after 
chloroquine.
Discussion
The treatment of P vivax malaria has changed little in the 
past 60 years. In most areas chloroquine plus primaquine 
is the ﬁ rst-line treatment, but this status quo is 
increasingly threatened by the emergence and spread of 
chloroquine-resistant P vivax. Unequivocal evidence now 
exists of high-grade chloroquine resistance on the islands 
of New Guinea and Indonesia,18,19 and evidence is 
accumulating for declining chloroquine eﬃ  cacy in many 
other P vivax-endemic areas. The extent of this threat is 
unclear because primaquine has intrinsic blood-stage 
activity, which could mask low-level chloroquine 
resistance, and modest reductions in therapeutic eﬃ  cacy 
can be either masked or accentuated by various 
methodological issues inherent in the study designs 
applied. Our meta-analysis draws attention to this 
heterogeneity and identiﬁ es several key factors 
contributing to the geospatial uncertainty in P vivax drug 
eﬃ  cacy (table 3).
Decreasing antimalarial eﬃ  cacy is shown by the ability 
of malaria parasites to grow in the presence of adequate 
bloodstream drug concentrations. At low levels of 
resistance an initial clinical response occurs, often 
followed by a return of illness caused by recrudescent 
parasitaemias (a late treatment failure, or late 
parasitological failure). The length of the interval from 
the start of treatment to parasite recrudescence depends 
Type of 
Report
Country Location Number of 
patients
Early treatment 
failure (%)
Day 28 
recurrence (%)
Comments
Osorio et al (2007) Trial Colombia Tarapaca 22 5·0% 10·0% ··
Ketema et al (2011) Trial Ethiopia Halaba 87 4·6% 13·8% ··
Tulu et al (1996) Trial Ethiopia Debre Zeit 459 2·0% 2·0% ··
Dunne et al (2005) Trial India New Delhi 102 2·0% 1·0% Early primaquine
Saravu et al (2012) Trial India Manipal 110 1·0% 1·1% Early primaquine
Singh et al (2000) Trial India Daltonganj 75 6·7% 22·7% Early primaquine
Srivastava et al (2008) Trial India Pansora 75 9·2% 9·2% ··
Baird et al (1997) Trial Indonesia Nabire 23 5·9% 70·4% ··
Maguire et al (2006) Trial Indonesia Armopa, Papua 232 20·0% 18·4% Early primaquine
Ratcliﬀ  et al (2007) Trial Indonesia Timika 40 16·0% 72·7% ··
Sumawinata et al (2003) Trial Indonesia Arso 29 24·0% 100·0% ··
Sutanto et al (2009) Trial Indonesia Alor 36 13·8% 43·3% ··
Sutanto et al (2010) Trial Indonesia Lampung 31 9·7% 65·2% ··
Tjitra et al (2002) Trial Indonesia Genyam 9 22·2% 88·9% ··
Than et al (1995) Trial Burma Mingaladon 50 6·0% 14·0% High chloroquine concentrations
Garg et al (1995) Report India Bombay 2 ·· ·· High chloroquine concentrations 
but slow clearance
Lee et al (2009) Report South Korea Seoul 2 ·· ·· Prolonged time to parasite 
clearance despite high chloroquine 
concentration
Schuurkamp et al (1989) Report PNG Olsobip 3 ·· ·· Still positive at day 7
Shah et al (2008) Report India Mumbai 1 ·· ·· Still positive on day 3
Singh et al (2002) Report India Jabalpur 1 ·· ·· Still positive on day 4
PNG=Papua New Guinea. ··=no data. References for all studies are shown in the appendix.
Table 2: Reports of early parasitological failures after chloroquine treatment of Plasmodium vivax
Chloroquine-resistant catagory 1
Chloroquine-resistant catagory 2
Chloroquine-resistant catagory 3
Chloroquine-sensitive
Pa
tie
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s w
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)
Chloroquine-
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Chloroquine-
resistant
Chloroquine-
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Chloroquine-
resistant
Day 2 Day 3
100
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0
Figure 4: Proportion of patients with parasitaemia on days 2 and 3
Articles
988 www.thelancet.com/infection   Vol 14   October 2014
on the pharmacology of the initial treatment regimen, 
the degree of drug resistance, and the level of host 
immunity.8 Increasing drug resistance enables parasite 
growth in high drug concentrations, which slows 
parasite clearance and shortens the interval to the ﬁ rst 
recurrence. In studies with a greater risk of recurrence 
by day 28 illness tended to recur sooner (rs=–0∙58). 
Highly resistant parasites continue to grow despite high 
blood con centrations of the drug, which results in early 
treatment failure. Our review identiﬁ ed 20 clinical trials 
and case reports in which this result was documented 
(table 2).
The epicentre for chloroquine-resistant P vivax is on 
the island of New Guinea, where studies have consistently 
shown high-grade resistance manifested by early clinical 
deterioration requiring hospitalisation, by delayed 
parasite clearance, and by early recurrent parasitaemia.18–20 
Several reports of severe and fatal vivax malaria have 
been published in the past few years.12,21 These reports 
occur more frequently from poorly resourced endemic 
regions where populations have poor access to health 
care and have a complex range of comorbidities. Delays 
in diagnosis, partially eﬀ ective treatment regimens, and 
failure to provide a radical cure are important factors in 
determination of morbidity and associated mortality of 
P vivax, especially that of severe anaemia in young 
children.22,23
Most P vivax clinical trials are done in malaria-endemic 
regions. Patients might therefore acquire new infections 
during follow-up. This risk is proportional to the 
duration of follow-up and the intensity of transmission. 
Relapses also occur, and again the risk is linked to 
duration of follow-up, host immunity, and the 
geographical location of the study. The risk of relapse 
varies substantially, from 50–80% in equatorial regions 
to 5–10% in temperate areas, where the ﬁ rst relapse 
occurs many months after the initial infection.24 
Molecular genotyping methods can discriminate 
between genetically homologous and heterologous 
infections.25–28 Our analysis identiﬁ ed ten studies that 
had used genotyping in analysis of P vivax drug eﬃ  cacy. 
However, genotyping cannot discriminate between a 
recrudescence of the blood-stage infection or a relapse 
with a homologous strain. Furthermore, as relapse can 
also be with a heterologous parasite strain, reliable 
distinction of the causes of recurrent infection within an 
endemic area is not possible at present.26,29 The derived 
estimates of clinical eﬃ  cacy for P vivax therefore are a 
combination of blood-stage schizonticidal activity and 
post-treatment prophylaxis suppressing early relapse or 
reinfection. The unadjusted risk of P vivax recurrence 
needs to be interpreted in light of the half-life of the 
treatment regimen, concomitant use of primaquine, the 
timing of recurrence, available molecular data, 
schizonticidal drug concentrations, entomological 
inoculation rates, and the epidemiology of relapse in the 
study area.
Recurrent parasitaemia within 28 days of chloroquine 
treatment does not necessarily imply chloroquine 
resistance. Sensitive parasites that have been exposed to 
insuﬃ  cient treatment because of an incorrect weight-
adjusted dose, poor quality drug, poor gastrointestinal 
absorption, or unusual pharmacokinetics can also 
recrudesce early. The deﬁ nitive diagnosis of chloroquine 
resistance therefore requires documentation of 
adequate drug exposure at the time of recurrence, to 
conﬁ rm the growth of parasites in concentrations of 
drug above the minimum inhibitory concentration.16 
However, pharma cokinetic analysis requires blood 
sampling and storage, access to an accredited laboratory, 
and the associated expenses. Fewer than a third of 
P vivax clinical studies reported were supported by 
pharmacokinetic analysis.
In falciparum malaria, the speed of parasite clearance 
correlates with the risk and timing of recrudescence and 
the infection’s transmission potential.8 This correlation 
has become a key clinical parameter for deﬁ nition of 
artemisinin resistance.30,31 Our analysis draws attention to 
the importance of the early parasite response after 
chloroquine treatment of P vivax; delayed parasite 
clearance (deﬁ ned by prevalence of microscopy detectable 
parasitaemia at 48 h) and early recurrence were strongly 
correlated (rs=–0∙72). Two studies have explored this 
correlation with individual patient’s data. Results of the 
ﬁ rst, in Papua New Guinea, showed that a P vivax 
parasite reduction ratio of less than 7∙4 predicted 
subsequent treatment failure with 70% sensitivity and 
Explanation Recommendation
Chloroquine sensitivity
Enrolment of patients without 
clinical disease
Host immunity in asymptomatic 
patients enrolled from cross-
sectional surveys might enable 
clearance of parasitaemia even after 
partly eﬀ ective drug treatment
Restrict eﬃ  cacy trials to patients 
presenting with clinical disease
Co-administration of early 
primaquine
Early primaquine has schizonticidal 
activity that can increase parasite 
clearance and prevent recrudescent 
infections
Primaquine treatment should be 
delayed until the end of the follow-
up
Short duration of follow-up Early evidence of resistance is shown 
by late recrudescence
Patients should be followed up for 
a minimum of 28 days
Incorrect diagnosis of chloroquine resistance
Incomplete treatment course Poor patient adherence Supervision of drug treatment
Dose of chloroquine too low Prescription of inadequate mg/kg 
dose
Documentation of exact dose of 
drug administered
Poor absorption of drug Either from poor quality drug or 
reduced gastrointestinal absorption
Measurement of drug blood 
concentrations on day 7 and the 
day of parasite recurrence
Poor drug quality Faulty product Conﬁ rmation of adequate drug 
concentrations, pharmacological 
assessment of study drugs and 
purchase only from certiﬁ ed, 
trusted producers
A protocol template for researchers to adapt for the study of P vivax antimalarial eﬃ  cacy is available online.15
Table 3: Factors contributing to the geospatial uncertainty in Plasmodium vivax drug eﬃ  cacy
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63% speciﬁ city.18 The second, from Thailand, showed 
that patients still parasitaemic at 48 h had a four-times 
increased risk of P vivax recurrence by day 28.32 The stage 
of parasites’ development and the speed of response were 
correlated, consistent with in-vitro data suggestive of a 
substantial stage speciﬁ city of action of chloroquine in 
P vivax.11,33 Because the proportions of parasites at 
diﬀ erent stages vary substantially between populations, 
the clinical consequences of parasite staging as a 
confounding factor for clinical eﬃ  cacy monitoring 
warrants further exploration.
A major advantage of parasite clearance rate as a 
marker for resistance is that it is not confounded by 
relapse or reinfection. In this Review, clearance of 
parasitaemia (by microscopy) in all patients by day 3 or in 
95% of patients by day 2 was 100% predictive of 
chloroquine sensitivity in the study population, as 
deﬁ ned by the day 28 recurrence rate. Further studies are 
needed to investigate early parasite clearance for 
monitoring of P vivax in diﬀ erent endemic settings, and 
the optimum sampling strategy to deﬁ ne it.
Most national guidelines recommend a combination of 
chloroquine for rapid blood-stage activity and a 14 day 
course of primaquine for the radical cure of the 
hypnozoite stages in P vivax malaria. Primaquine is 
usually started with the initial dose of chloroquine. 
Primaquine has activity against both blood and liver 
stages, including against chloroquine-resistant strains.34,35 
Primaquine might therefore provide a good therapeutic 
response even when combined with a compromised 
schizonticidal partner drug. Our analysis identiﬁ ed 
14 studies that compared chloroquine monotherapy with 
chloroquine plus primaquine. Patients treated with the 
combination regimen had a signiﬁ cantly lower risk of 
recurrence by day 28 (OR 0∙27) than did patients given 
monotherapy. Although this diﬀ erence was most notable 
for patients in the Indonesian studies with low 
chloroquine eﬃ  cacy, the same decreases were apparent 
in all but two studies, both of which gave very low dose 
primaquine regimens (ﬁ gure 2). Almost a quarter of the 
studies assessing chloroquine eﬃ  cacy also treated 
patients with the early administration of primaquine, 
and nearly all of these studies reported low rates of 
recurrent parasitaemia at day 28. Studies with early 
primaquine are therefore unhelpful in predicting 
chloroquine resistance. These ﬁ ndings emphasise the 
additional value of primaquine and the importance in 
therapeutic assessments (as opposed to routine 
treatment) of delaying, when possible, the administration 
of primaquine until the end of treatment, if the primary 
objective is to detect underlying chloroquine eﬃ  cacy.
Drug-resistant plasmodia often occur in areas of high 
drug pressure and low parasite prevalence. When 
incidence is low, recruitment of patients to studies might 
be slow. Some investigators have used active recruitment, 
seeking out patients with parasitaemia in cross-sectional 
surveys of target populations. However, patients 
identiﬁ ed in this manner have signiﬁ cantly lower 
peripheral parasitaemias compared with those of 
symptomatic patients presenting to a health-care facility. 
Since the initial parasitaemia before treatment is a major 
determinant of therapeutic eﬃ  cacy, studies enrolling 
patients through active case detection are likely to 
underestimate resistance. Individuals with low-grade 
parasitaemias probably have suﬃ  cient immunity to 
suppress symptomatic disease, thereby reducing the risk 
of recrudescence even from drug-resistant parasites. 
Antimalarial eﬃ  cacy studies should aim to document the 
clinical response in symptomatic patients. Although a 
high risk of recurrence in patients recruited from surveys 
can draw attention to areas of potential drug-resistant 
P vivax, the absence of recurrences from such studies 
should not be held as evidence of drug sensitivity.
Studies of chloroquine eﬃ  cacy for P vivax were 
categorised according to the risk of recurrence at day 28, 
the 95% CI on this estimate, the documentation of blood 
drug concentrations, the enrolment of patients with 
symptomatic disease, and the early co-administration of 
primaquine. Our deﬁ nitions were conservative, with data 
excluded from almost 40% of studies that we thought 
could be confounded. Almost half of the informative 
studies suggested evidence of reduced chloroquine 
eﬃ  cacy. 15 of these studies and ﬁ ve case reports 
documented evidence of early treatment failure (table 2).
The geographical extent of chloroquine-resistant 
P vivax suggests that chloroquine resistance has emerged 
or spread in many P vivax-endemic countries (ﬁ gure 3). 
These individual reports warrant closer scrutiny of the 
raw data, review of quality-control procedures, and 
repetition, preferably in randomised control trials with 
alternative treatment regimens. The epicentres of 
chloroquine-resistance are the eastern provinces of 
Indonesia, although reports of reduced susceptibility are 
apparent across the archipelago. In the past 5 years, 
convincing evidence has been reported of chloroquine 
resistance P vivax from Thailand,32 Cambodia,36 Ethiopia,37,38 
and South America.39 By contrast, the reports from the 
Indian subcontinent (India, Afghanistan, and Pakistan) 
are mostly reassuring. Several reports have suggested 
either low-grade chloroquine resistance or sporadic 
reports of early treatment failure;40,41 however, these 
reports have usually not been substantiated on further 
investigation.
The widespread emergence and spread of chloroquine 
resistance should cause substantial concern. The 
combination of chloroquine plus primaquine retains 
good eﬃ  cacy in areas with moderate levels of chloroquine 
resistance, and is the default in most P vivax endemic 
countries. However, in practice, clinicians are often 
reluctant to prescribe primaquine because of fears of 
haemolysis.42 Furthermore, even when primaquine is 
prescribed, patients might not adhere to the standard 
14 day course. Alternative treatment regimens are 
available. Most of the artemisinin-based combination 
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therapies have proven eﬃ  cacy against chloroquine-
resistant strains of P vivax.20,43 Although more costly, a 
universal policy of artemisinin-based combination 
therapies in areas co-endemic for both P falciparum and 
P vivax has many advantages. The rationale for the use of 
artemisinin-based combination therapies for all malaria 
infections is compelling in areas where chloroquine 
resistance is established.44
P vivax continues to inﬂ ict a substantial burden on the 
malaria-endemic world with the morbidity and mortality 
related to its propensity to cause recurrent infections. 
Frequent recurrences of vivax malaria result from the use 
of partially eﬀ ective blood-stage treatment and our poor 
ability to achieve radical cure safely.45 In this context, 
enhanced monitoring of decreasing drug eﬃ  cacy for 
P vivax malaria is essential. Enhanced monitoring will 
require standardised methods and novel approaches for 
more precise quantiﬁ cation of drug eﬃ  cacy. A tendency 
exists to assume that present antimalarial treatment 
regimens continue to retain eﬃ  cacy long after evidence 
of decreasing antimalarial activity has begun to emerge. 
Inadequate surveillance methods compounded by 
complacency have delayed the detection and containment 
of chloroquine-resistant P falciparum, with devastating 
public health consequences. If a repetition of history is to 
be avoided, then the threat of chloroquine-resistant 
P vivax needs to be acknowledged and greater resources 
applied to develop standardised and validated methods 
for its detection, characterisation, and containment.
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